John P. Schmid - 10 May 2024 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
10 May 2024
Net transactions value
+$10,314
Form type
4
Filing time
10 May 2024, 16:04:26 UTC
Previous filing
25 Mar 2024
Next filing
05 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $10,314 +5,400 +49% $1.91 16,400 10 May 2024 By: The Schmid Family Trust dated August 15, 2017 F1
holding XERS Common Stock 63,159 10 May 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.